Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.41 |
| ▸ | CYP46A1 | Q9Y6A2 | 4/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045118 | 0.80 | CYP46A1 (0.61) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL1152579 | 0.80 | CYP46A1 (0.61) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL29399335 | 0.80 | CYP46A1 (0.61) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL6905458 | 0.80 | PDE7A (0.48) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL6905795 | 0.66 | PDE7A (0.48) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL6905802 | 0.66 | PDE7A (0.48) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL6905798 | 0.66 | PDE7A (0.48) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL29393057 | 0.64 | PDE7A (0.45) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL4088810 | 0.64 | PDE7A (0.45) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 | |
| SCHEMBL1046528 | 0.64 | PDE7A (0.45) | PDE7ACYP46A1AKR1B1NR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637693-B2 | Anellosomes and methods of use | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260098280-A1 | SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLES | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12540337-B2 | Surface-modified viral particles and modular viral particles | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20260009050-A1 | ANELLOSOMES FOR DELIVERING SECRETED THERAPEUTIC MODALITIES | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250320465-A1 | COMPOSITIONS COMPRISING MODIFIED ANELLOVIRUS CAPSID PROTEINS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250257368-A1 | IN VITRO ASSEMBLY OF ANELLOVIRUS CAPSIDS ENCLOSING RNA | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250171807-A1 | SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2025080985-A1 | TISSUE SPECIFIC ANELLOVECTOR DELIVERY | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| EP-4526326-A2 | COMPOSITIONS COMPRISING MODIFIED ANELLOVIRUS CAPSID PROTEINS AND USES THEREOF | Flagship Pioneering Innovations V, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20250059559-A1 | SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-115867678-A | Methods for identifying and characterizing dactyloviruses and uses thereof | 旗舰先锋创新V股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230048858-A1 | ANELLOSOMES FOR DELIVERING SECRETED THERAPEUTIC MODALITIES | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-02-16 | — | — | US | disclosed |
| US-20220372519-A1 | IN VITRO ASSEMBLY OF ANELLOVIRUS CAPSIDS ENCLOSING RNA | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-11-24 | — | — | US | disclosed |
| WO-2022241013-A1 | ANELLOVECTORS AND METHODS OF USE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022170195-A1 | HYBRID AAV-ANELLOVECTORS | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022140560-A1 | IN VITRO ASSEMBLY OF ANELLOVIRUS CAPSIDS ENCLOSING RNA | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3433380-B1 | DRUGS, PHARMACOGENOMICS AND BIOMARKERS FOR ACTIVE LONGEVITY | UNIV INDIANA RES & TECH CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20220073950-A1 | ANELLOSOMES FOR DELIVERING PROTEIN REPLACEMENT THERAPEUTIC MODALITIES | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-03-10 | — | — | US | disclosed |
| US-20220042042-A1 | ANELLOSOMES AND METHODS OF USE | FLAGSHIP PIONEERING, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20220040117-A1 | ANELLOSOMES FOR DELIVERING INTRACELLULAR THERAPEUTIC MODALITIES | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637693-B2 | Anellosomes and methods of use | TAP2, UPF1, TAP1 | PDE7A 3304/4885CYP46A1 4558/4885AKR1B1 3774/4885 |
| US-20260009050-A1 | ANELLOSOMES FOR DELIVERING SECRETED THERAPEUTIC MODALITIES | UPF1, EXOSC4, STING1 | PDE7A 4211/4885CYP46A1 4417/4885AKR1B1 3310/4885 |
| US-12540337-B2 | Surface-modified viral particles and modular viral particles | APOL1, SAAL1, UFL1 | PDE7A 3896/4885CYP46A1 4630/4885AKR1B1 3754/4885 |
| US-20260098280-A1 | SURFACE-MODIFIED VIRAL PARTICLES AND MODULAR VIRAL PARTICLES | SAAL1, APOL1, UFL1 | PDE7A 4234/4885CYP46A1 4662/4885AKR1B1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.